Bioxytran and University of Georgia Influenza A virus subtype H5N1 Research
Analysis based on 8 articles · First reported Feb 23, 2026 · Last updated Feb 24, 2026
This collaboration between Bioxytran and the University of Georgia to combat the Influenza A virus subtype H5N1 bird flu virus could significantly impact the biotechnology and agriculture sectors. A successful antiviral treatment for Influenza A virus subtype H5N1 would mitigate billions in losses from culling and positively affect Bioxytran's stock and the global food supply.
Bioxytran, Inc., a clinical-stage biotechnology company, has initiated a research collaboration with the University of Georgia to evaluate its lead drug candidate, PHM23, for blocking the Highly Pathogenic Avian Influenza (HPAI) Influenza A virus subtype H5N1 virus, commonly known as bird flu. This partnership is part of a $100 million grant from the United States===United States Department of Agriculture's HPAI Poultry Innovation Grand Challenge. PHM23, a novel galectin antagonist, aims to neutralize the virus by blocking viral spike proteins from attaching to host cells. The research is led by Dr. Daniela Rajao at the University of Georgia. This initiative seeks to provide a humane and sustainable solution to Influenza A virus subtype H5N1 outbreaks, which currently necessitate mass culling and result in billions of dollars in economic losses, offering a more effective alternative for rapid containment and mitigating devastating economic impacts on farmers and consumers.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard